Key result
St. Jude Medical valves yield ~88% mid-term survival with low thromboembolism and no mechanical failures.
Population
228 patients undergoing isolated aortic or mitral valve replacement, age ranging from 6 to 84 years.
Design
Cohort
Follow-up
1 to 54 months (mean 19.6 +/- 12.4 months)
Authors
Loading...
Supports mid-term St. Jude prosthesis use in valve replacement; leaves open randomized comparisons to alternatives.
Cohort (n=228)
No
The St. Jude Medical prosthesis demonstrates excellent mid-term survival, low thromboembolic rates, and significant functional improvement in patients undergoing aortic or mitral valve replacement.
Crawford et al. (1984) conducted a cohort in Valvular heart disease requiring aortic or mitral valve replacement (n=228). St. Jude Medical prosthesis was evaluated on Actuarial survival at 42 months. Valve replacement with the St. Jude Medical prosthesis yielded 42-month actuarial survival of 86.7% (aortic) and 89.3% (mitral), with low thromboembolism rates and no mechanical failures.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: